Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00806156 · ClinicalTrials.gov registry record · Phase 2
Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer
A Phase 2 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 178
- Enrollment target
NCT00806156 is a Phase 2 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 178 participants.
The verdict
NCT00806156, a Phase 2 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer. Approximately 70 patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be administered at a dose level of 145 mg/m\^2 in both arms. In Arm A, NKTR-102 will be given on a q14d schedule. In Arm B, NKTR-102 will be given on a q21d schedule. After the initial 70 patients have been enrolled, Arm B will enroll approximately 110 additional patients.
Interventions
- DRUG NKTR-102 q14d
- DRUG NKTR-102 q21d
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2008-10 |
| Est. Completion | 2013-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00806156
The ClinicalTrials.gov registry entry for NCT00806156 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NKTR-102 q14d is the first listed.
NCT00806156 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00806156 about?
NCT00806156 is a clinical study titled "Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Ovarian Cancer". This is a multicenter, open-label, two-arm, 2-stage, Phase 2 study of NKTR-102 in patients with metastatic or locally advanced platinum-resistant ovarian cancer. Approximately 70 patients will be randomized 1:1 into one of two treatment arms. NKTR-102 will be administered at a dose level of 145 mg/...
What is the current status of trial NCT00806156?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 178 participants. The study started on 2008-10. Estimated completion is 2013-01.
What interventions are being tested in trial NCT00806156?
The interventions under investigation include: NKTR-102 q14d (DRUG), NKTR-102 q21d (DRUG).
Who is sponsoring clinical trial NCT00806156?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.